#United States #New York #Class Action #Faruqi & Faruqi #Mereo BioPharma

Mereo BioPharma Investors Alerted

In a significant update for shareholders of Mereo BioPharma Group plc (NASDAQ: MREO), the prominent national securities law firm, Faruqi & Faruqi, LLP, is raising awareness about an impending deadline related to a federal securities class action lawsuit. Investors are encouraged to take action before April 6, 2026, to participate in this legal matter, which could bring to light potential claims related to the company's alleged misconduct.

As reported, Faruqi & Faruqi is investigating claims against Mereo BioPharma following a series of troubling disclosures regarding the company’s Phase 3 clinical trials. Specifically, the firm points to allegations that Mereo BioPharma and its executives may have violated federal securities laws by misrepresenting or omitting crucial information about the outcomes of their ORBIT and COSMIC programs.

On December 29, 2025, Mereo announced that two of its Phase 3 studies involving setrusumab had failed to achieve their primary objectives - a disheartening development for investors who had anticipated favorable results. The studies aimed to demonstrate a reduction in annualized clinical fracture rates when compared to placebo and bisphosphonate control groups. While the secondary outcomes showed statistically significant improvements in bone mineral density, the primary endpoint misses led to a dramatic 87.64% drop in Mereo's share price, closing at merely $0.28 per share following the announcement.

Faruqi & Faruqi emphasizes the importance of finding a lead plaintiff, who serves as a representative for the class of investors, guiding the litigation process. Those who purchased or acquired securities in Mereo BioPharma between June 5, 2023, and December 26, 2025, are particularly urged to come forward to discuss their legal options.

James (Josh) Wilson, a senior partner at Faruqi & Faruqi, invites investors who have suffered losses to reach out directly for assistance. The firm can be contacted through phone at 877-247-4292 or 212-983-9330 for more information related to this ongoing legal situation. Furthermore, anyone with knowledge regarding Mereo BioPharma's behavior, including whistleblowers, former employees, and shareholders, is encouraged to contact the firm.

Investors are reminded that there is no downside in choosing to be a lead plaintiff; even if they choose not to take on this role, their potential recovery from the class action remains unaffected. For updates and nuances regarding the class action details, interested individuals can visit Faruqi Law's MREO Page.

Faruqi & Faruqi has established itself as a strong advocate for investor rights since its founding in 1995, recovering hundreds of millions for its clients. This investigation signifies yet another effort to ensure that the interests of Mereo BioPharma's investors are diligently represented and pursued.

In the world of finance, staying informed and proactive is crucial, especially in light of potential legal actions that may affect investments. Mereo BioPharma shareholders should heed this alert and act accordingly before the looming deadline.